Finance

Lists
Why is CRVS down 4.03%?
Dive Deeper
CRVS:NASDAQ
Corvus Pharmaceuticals Inc
$9.99
-4.03%
(-0.42) 1D
Oct 8, 9:57:56 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRVS...
Open
$10.15
High
$10.31
Low
$9.94
Mkt. cap
840.37M
Avg. vol.
1.11M
Volume
150.63K
52-wk high
$26.95
52-wk low
$6.39
EPS
-$0.62
Beta
1.44
Shares outstanding
84.12M
No. of employees
37
Open
$10.15
High
$10.31
Low
$9.94
Mkt. cap
840.37M
Avg. vol.
1.11M
Volume
150.63K
52-wk high
$26.95
52-wk low
$6.39
EPS
-$0.62
Beta
1.44
Shares outstanding
84.12M
No. of employees
37
News stories
From web sources and news partners
Stock Traders Daily
Stock Traders Daily
·
17 hours ago
Understanding Momentum Shifts in (CRVS)
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, California, United States
SectorBiotechnology
Websitecorvuspharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CRVS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CRVS in the last 3 months.
Highest
Current $9.99
$33.00 (+230.33%)
Average
$29.50 (+195.30%)
Lowest
$27.00 (+170.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
$30.00
+200.3%
08/11/2026
Sean Lee CFA
H.C. Wainwright
Buy
Maintained
$27.00
+170.3%
08/10/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$33.00
+230.3%
08/07/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$33.00
+230.3%
08/07/2026
Etzer Darout
Barclays
Buy
Maintained
$28.00
+180.3%
08/07/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$40.00
+300.4%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.45M
9.94M
11.18M
15.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.12M
2.28M
3.70M
3.33M
Operating expense
10.57M
12.22M
14.88M
19.30M
Total operating expenses
10.57M
12.22M
14.88M
19.30M
Operating income
-10.57M
-12.22M
-14.88M
-19.30M
Other non operating income
-
-
-
-
EBT including unusual items
-10.16M
-12.32M
-13.69M
-17.96M
EBT excluding unusual items
-10.16M
-12.32M
-13.69M
-17.96M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10.16M
-12.32M
-13.69M
-17.96M
Net profit margin
-
-
-
-
Earnings per share
-0.12
-0.15
-0.15
-0.19
Interest and investment income
738.00K
603.00K
1.78M
2.05M
Interest expense
-
-
-
-
Net interest expenses
738.00K
603.00K
1.78M
2.05M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.54M
-12.19M
-14.85M
-19.26M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps